Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Challenger (ASX:CGF) share price falls upon Q3 update

The Challenger Ltd (ASX: CGF) share price drops despite recording solid growth in the third quarter. Why has the Challenger share price dipped?
Wealth

The Challenger Ltd (ASX: CGF) share price drops despite recording solid growth in the third quarter. Why is the Challenger share price dipping?

Challenger share price

Source: Rask Media CGF 2-year share price chart

Challenger records growth in sales

Following on from its HY21 results, Challenger appears to be experiencing solid growth in sales.

The value of group assets under management jumped by 8% for the third quarter of FY21, which currently exceeds $100 billion.

The Challenger Life segment comprised of annuities and guaranteed retirement income products posted record quarter annuity sales of $1.6 billion. The value of these assets also surged by 6% for the same period.

The company notes its fund management arm further solidified its position as the fastest-growing active manager in Australia.

Total funds under management grew by 9% during the quarter and received net flows of $7 billion.

Challenger’s outlook

Challenger remains on track to achieve its FY21 normalised profit guidance but at the lower end of the guidance range. This is due to a tighter credit spread environment.

What’s normalised profit guidance? This is often used to remove one-off items to provide investors with a picture of what profit is under ‘normal’ operating conditions.

The business is currently responding to such conditions by considering adjustments to its annuity pricing.

My thoughts

It appears the market has punished Challenger for advising that it would only be able to meet the lower end of the normalised profit guidance range.

Rathern than focusing on this metric, I think it’s more important to monitor Challenger’s investment performance and strategy.

As outlined in my article covering the HY21 results, investors should be wary of the level of investment revenue against the level of Life contract claims and expenses.

Instead of Challenger, I suggest getting a free Rask account and accessing our full stock reports. Click this link to join for free and access all of our free analyst reports.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content